1. CME-Certified 2012 Hematology Tumor Board Series: Practical Solutions to Current Clinical Challenges in B-Cell Lymphoma

4. Case 1 Middle-Aged Man With Adenopathy

7. Case 1 What Would You Recommend for This Patient?

8. Case 1 What Would You Recommend for This Patient?

10. Is Watch-and-Wait Still Valid Option in Rituximab Era? Yes!

13. Watch-and-Wait It Is Critical to Know When the Patient Needs to Be Treated!

16. Is PET Scan Useful to Help Direct Biopsy? Yes!

17. At This Point, Patient Needs to Be Treated Does He Need R-Chemo
At This Point, Patient Needs to Be Treated Does He Need R-Chemo? If Yes, Which One?

23. Combination Biologic Therapies Getting More “Mileage” Out of Rituximab Without Chemotherapy

27. Is Maintenance or Some Form of Consolidation Necessary
Is Maintenance or Some Form of Consolidation Necessary? What Should We Do for This Patient at This Point?

30. Case 2 66-Year-Old Woman With Relapsed/Refractory CLL/SLL

33. Case 2 How Would You Treat This Patient?

35. Case 2 Abnormal Cytogenetics

37. Case 2 What Is Your Recommendation for Treatment
Case 2 What Is Your Recommendation for Treatment? What About Novel Agents?

40. Case 3 69-Year-Old Man With Dysphagia

43. Case 3 How Would You Treat This Patient?

49. Case 4 Young Woman With Inguinal Mass

53. When Is FISH Analysis for MYC Translocations Warranted in Patients With DLBCL? When CD10+ or BCL6+ and 11− and a proliferation index > 80%!

55. Case 4 Should We Consider CNS Prophylaxis for This Patient?